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Calpain is a mediator of myocardial injury in experimental and sodium and water retention are thought to be impor-
uremia: Is it activated by endogenous ouabain? tant factors. We thought it likely that calpain, a Ca2-
Background. Incidence of cardiovascular disease is more requiring cysteine protease that is a known mediator ofthan 20-fold higher in patients with chronic renal failure than
cell death, might also play a role. This is because long-in aged-matched individuals with normal renal function. Little
term studies in our laboratory have revealed that Ca2is understood about the causes or the mechanism of uremia-
induced cardiovascular injury, but the involvement of calpain homeostasis is altered in myocytes from uremic rats com-
as a possible mediator has recently been under investigation. pared with pair-fed, sham-operated controls [3]. There
Mean calpain activity was found to be 3.4-fold higher in the is also evidence indicating that intracellular calciumhearts of uremic rats than in control or spontaneously hyperten-
([Ca2]j) is increased in the hearts of uremic patientssive (SHR) rats. In addition, calpain activity was found to be
stimulated in myoblasts (Girardi) treated with media enriched compared with healthy subjects [4]. A likely outcome of
with uremic serum compared with cells treated with serum raised [Ca2]j in the uremic myocardium is the activation
from healthy volunteers. In this study, we assessed the impact of calpain, which may, in turn, lead to cell death. Calpain
of calpain activation in uremia and explored the possibility that
activation has been identified in numerous injuriouscalpain might be activated in uremia by endogenous ouabain.
states in which [Ca2]j is known to be elevated, includingOuabain is known to be elevated in uremia and is strongly
associated with left ventricular hypertrophy in essential hyper- traumatic brain injury, Alzheimer’s disease, and ischemic
tension. stroke [5].
Methods. Calpain activity was measured in situ in human- Calpain has many protein substrates that are closelyderived myoblasts treated with low doses of ouabain similar
associated with the structural integrity of the cell. It isto those concentrations found in uremic patients.
feasible that the activation of calpain may help facilitateResults. Low concentrations of ouabain (10 nmol/L) caused
a highly significant increase in calpain activity, which could be the cellular structural remodeling that leads to the devel-
completely inhibited by the simultaneous chelation of intracel- opment of LVH. Indeed, some evidence of a role for
lular and extracellular Ca2, and by the chelation of extracellu-
calpain in experimentally-induced cardiac hypertrophylar Ca2 alone.
does exist [6]. Furthermore, Ca2 channel blockers haveConclusions. Calpain activity can be stimulated by nanomo-
lar concentrations of ouabain due to an influx of extracellular been shown to be effective in reversing LVH, indepen-
Ca2. As circulating ouabain is known to be elevated in uremia dent of anti-hypertensive effects, in patients with essen-
and strongly associated with LVH remodeling, we hypothesize tial hypertension [7].
that endogenous ouabain might be one of the factors that
Recent efforts in our laboratory have focused on thefacilitates the remodeling of the left ventricle in patients with
activity of calpain in the hearts of sham-operated controlrenal failure.
rats, spontaneously hypertensive rats (SHR), and rats
rendered uremic by 5/6th nephrectomy. We have also
studied the effect of uremic serum treatment in human-Uremia has long been associated with a high incidence
derived myoblasts (Girardi) in the presence and absenceof cardiovascular mortality [1] that is frequently pre-
of calpain inhibitors. Mean calpain activity was foundceded by left ventricular hypertrophy (LVH), which is
to be 3.4-fold higher in the uremic group of animalsrecognized as an independent risk factor for survival [2].
compared to both the control and SHR groups. CalpainLittle is known of the mechanism of how uremia induces
activity was significantly higher in the myoblasts treatedLVH, but anemia, arteriovenous shunts, hypertension,
with media enriched with uremic serum than those
treated with media enriched with serum from healthy
Key words: calpain, ouabain, LVH. human volunteers. Uremic serum treatment caused a
four-fold rise in DNA fragmentation in the myoblasts, 2003 by the International Society of Nephrology
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which could be significantly attenuated with three dis- plate to ensure that only cellular calpain activity was
measured.tinct calpain inhibitors. We concluded that calpain was
a likely mediator of uremia-induced myocardial injury
Materials[8]. This article assesses the implications of calpain as a
mediator of uremia-induced cardiovascular injury and Unless otherwise stated in the text, all chemicals were
obtained from the Sigma-Aldrich Chemical Companydescribes a possible mechanism by which calpain can be
activated in patients with chronic renal failure. (Poole, Dorset, United Kingdom). AnalaR grade wa-
ter (VWR International, Ltd., Leic, United Kingdom)
was used for all aqueous solutions. BAPTA-AM was
METHODS
obtained from CN Biosciences (Beeston, Notts, United
Cell culture Kingdom).
Human-derived Girardi cells were obtained from the
StatisticsEuropean Collection of Animal Cell Cultures (ECACC,
Porton Down, United Kingdom). Cells were cultured in All data are presented as mean  SE of N observa-
tions, with N representing the number of samples stud-EMEM media containing 2 mmol/L L-glutamine, 10%
fetal calf serum (FCS; Invitrogen, Ltd., Paisley, United ied. Data were analyzed for normality using Analyze-it
software for Microsoft Excel (version 1.62, Leeds, UnitedKingdom), 1% non-essential amino acids (NEAA) from
GIBCO (Invitrogen, Ltd.), and antibiotic (100 U/mL Kingdom), followed by unpaired Student’s t test. When
comparing the mean of the two groups, P  0.05 waspenicillin, 100 g/mL streptomycin, and 0.25 g/mL am-
photericin B) in 75 cm3 tissue culture flasks. considered significant.
Incubation media
RESULTS
Experiments were performed using enriched EMEM
In situ calpain assaymedia as described above, without antibiotics, with Ca2
chelators, ouabain octahydrate, or controls (water or Calpain activity in cultured myoblasts was found to
DMSO when appropriate). rise in a dose-dependent manner when incubated with
nanomolar concentrations of ouabain. The increase in
Calpain activity in situ activity relative to control-treated cells reached signifi-
A 75 cm3 tissue culture flask of subconfluent cells were cance at ouabain concentrations of 10 nmol/L and above
treated with 5 mL of 0.25% trypsin EDTA and seeded (Fig. 1A, 10 nmol/L, P 0.05; 100 nmol/L, P 0.01; N
into 6-well tissue culture plates with 1 mL of EMEM 6). Subsequently, 10 nmol/L of ouabain was added to a
containing 10% FCS media/well. After 24 hours, the number of plates and the in situ calpain activity was
wells consisted of a monolayer of cells. The media was consistently and significantly raised when compared to
then removed and replaced with 2 mL of fresh media control-treated cells (relative fluorescence units, control
containing 10% FCS to the Girardi cell monolayers and 278  51.6, ouabain 540  80.7, P  0.01; N  18).
to a blank plate (without cells). To all plates 50 mol/L EGTA (1 mmol/L), which is a cell impermeable Ca2
of the calpain specific inhibitor calpeptin (in DMSO) chelator, did not inhibit baseline calpain activity, but
was added to three wells while the remaining three wells (almost completely) prevented the increase in calpain
were treated with the same volume of DMSO (28 L, activity due to 10 nmol/L ouabain (Fig. 1B). BAPTA-AM
1.4%). Ouabain octahydrate was added (dissolved in (50 mol/L), which is cell permeable and can therefore
water) to all wells and the same volume of water (20 L) chelate Ca2 extracellularly and intracellularly, com-
to control and blank plates. After 15 min preincubation pletely inhibited all of the calpain activity in both control-
at 37C in a humidified environment of air/CO2 (19:1), and ouabain- treated cells.
10 L of the cell permeable calpain substrate N-succinyl-
Leu-Leu-Val-Tyr-AMC (1 mmol/L in DMSO) was added
DISCUSSIONto all wells in all the plates. After three hours’ incubation,
We have previously found that calpain activity is ele-fluorescence was detected at 380 nm excitation and 460
vated in uremic rat hearts and in myoblasts treated withnm emission on a fluorescence plate reader (BMG Fluor-
media enriched with uremic serum compared to controlostar; BMG Labtechnologies, Ltd., Aylesbury, United
groups [8]. In this study, we describe the surprising find-Kingdom). The calpain activity was determined for each
ing that nontoxic concentrations of ouabain stimulatedtreatment as the difference between the mean fluores-
calpain activity in situ in myoblasts (Fig. 1A). We hypoth-cence in the samples without the calpain inhibitor, and
esize that the elevated circulating concentrations of oua-those with the inhibitor. The calpain activity of each
bain found in uremia might be responsible for inducingmedia solution without cells (blank plate) was then sub-
tracted from the calpain activity in the tissue culture calpain activity, and might therefore be an initiator of
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an ionic pump. However, much recent work has revealed
that nanomolar concentrations of ouabain can influence
signal transduction pathways without inhibiting NaK-
ATPase function [13, 14], while earlier work by Zhu et al
[15] demonstrated that 1 nmol/L of ouabain could induce
increases in [Ca2]j in rat vascular smooth muscle cells.
Ouabain has been shown to be elevated in a subset
of patients with essential hypertension, and a high plasma
ouabain concentration was found to be associated with
an increase in LVH [16]. This is supported by reports
of raised circulating digoxin immunoreactivity concen-
trations in patients with LVH [17, 18]. It is likely that
the digoxin assays used in these studies were also de-
tecting the presence of endogenous ouabain. Further-
more, ouabain has been shown to induce hypertrophy
in cultured cell myocytes and to alter cardiac gene ex-
pression [19].
A likely consequence of elevated calpain activity in
the uremic myocardium is an increase in cell death. It
is also plausible that calpain might be one of the factors
that facilitate the remodeling of the left ventricle in pa-
tients with renal failure, since cell cytoskelatal proteins
such as ankyrin, actin, and fodrin are known substrates
for calpain. As these proteins are responsible for the
positioning and orientation of the NaK-ATPase on
the cell membrane, it is likely that their degradation
upon calpain activation might result in the reduction of
cell membrane-bound NaK-ATPase. Such a reduction
in left ventricular NaK-ATPase concentration is known
Fig. 1. The in situ calpain activity of monolayers of Girardi cells incu- to occur in ischemic heart disease [20].
bated with enriched EMEM media containing increasing concentrations To summarize, we have previously demonstrated that
of ouabain after 3 hours incubation. (A) Bars with different letters are calpain activity is elevated in vivo in uremic rats com-significantly different from one another (P  0.05; N  6), while bars
pared with both sham-operated controls and SHRs. Wecontaining the same letter are not statistically different. (B) Illustrated
is the manner in which 10 nmol/L ouabain significantly increases calpain have also shown that calpain activity and DNA fragmen-
activity, which can be inhibited by the calcium chelators BAPTA-AM tation are raised in human-derived myoblasts treatedand EGTA (P  0.05; N  6).
with media enriched with uremic serum compared with
those treated with serum from healthy human volun-
teers. Incubating the uremic serum-treated myoblasts
the cardiovascular injury found in renal failure. If so, with three chemically distinct calpain inhibitors caused
ouabain could thereby be thought of as a novel uremic a reduction in calpain activity and DNA fragmentation.
toxin. The observation that EGTA could inhibit the oua- Here we have presented evidence of ouabain’s ability
bain-induced increase in calpain activity (Fig. 1B) indi- to activate calpain in human-derived myoblasts at con-
cates that calcium influx is the likely mechanism by which centrations similar to those found in uremic patients.
ouabain acts. The chelation of extracellular Ca2 (and extracellular
Ouabain, a cardiac glycoside once considered to be and intracellular together) prevents this ouabain-induced
solely an exogenous plant toxin, has now been generally calpain activity, which suggests that Ca2 influx is the
accepted to be an endogenous hormone [9] although its mechanism by which calpain activity is stimulated.
physiologic and pathophysiologic role is still unclear.
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